- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dr. Lal PathLabs Ltd (DLPA)
Dr. Lal PathLabs Ltd stock price live, this page displays NSE DLPA stock exchange data. View the DLPA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Dr. Lal PathLabs Ltd real time stock price chart below.
What Is the Dr. Lal PathLabs Ltd Stock Price Today?
The Dr. Lal PathLabs Ltd stock price today is 1,950.40.
What Is the Stock Symbol for Dr. Lal PathLabs Ltd?
The stock symbol for Dr. Lal PathLabs Ltd is "DLPA."
What Stock Exchange Does Dr. Lal PathLabs Ltd Trade On?
Dr. Lal PathLabs Ltd is listed and trades on the NSE stock exchange.
Is Dr. Lal PathLabs Ltd a Good Stock to Buy?
Determining whether Dr. Lal PathLabs Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DLPA quote. (ISIN: INE600L01024)
What Is the Dr. Lal PathLabs Ltd Stock Price Today?
The Dr. Lal PathLabs Ltd stock price today is 1,950.40.
What Is the Stock Symbol for Dr. Lal PathLabs Ltd?
The stock symbol for Dr. Lal PathLabs Ltd is "DLPA."
What Stock Exchange Does Dr. Lal PathLabs Ltd Trade On?
Dr. Lal PathLabs Ltd is listed and trades on the NSE stock exchange.
Is Dr. Lal PathLabs Ltd a Good Stock to Buy?
Determining whether Dr. Lal PathLabs Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DLPA quote. (ISIN: INE600L01024)
1,950.40
+8.30(+0.43%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,930.60
1,971.40
52 wk Range
1,272.60
2,038.60
DLPA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,930.601,971.40
52 wk Range
1,272.602,038.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.82%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.82%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
DLPA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
1,976.54
Upside
+1.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
21 Buy
3 Hold
2 Sell
Ratings:
26 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1,976.54
(+1.34% Upside)
Dr. Lal PathLabs Ltd Earnings Call Summary for Q1/2027
- Dr. Lal PathLabs Q1 FY27 revenue rose 19.1% YoY to INR 798 crore; PAT up 27.2% to INR 170 crore, fastest growth in four years.
- EBITDA climbed 28.6% to INR 247 crore with margin at 31%; patient volumes grew 8.2%, revenue per patient increased 10% to INR 968.
- Management raised FY27 revenue guidance to mid-teens growth from early-teens; EBITDA margin target held at 27-28% despite reinvestment plans.
- Company plans 12-15 new labs, 3-4 radiology centers in FY27; capex of INR 140-150 crore focused on acquisitions in underrepresented regions.
- Stock surged 4.27% to $1,759.2, near 52-week high; CGHS/ECHS pricing adds 2-3% to realization growth for 2-3 more quarters.
Last Updated: 07/24/2026, 09:20 PM
Read Full TranscriptEarnings
Latest Release
Jul 24, 2026
EPS / Forecast
10.10 / 8.69
Revenue / Forecast
7.98B / 7.58B
Compare DLPA to Peers and Sector
Metrics to compare | DLPA | Peers Peers - average of corresponding metrics from companies closely matching DLPA: MAXHEALTH, METROPOLIS, INDRAMEDCO, NH, ASTERDM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDLPAPeersSector |
|---|---|---|---|---|
P/E Ratio | 60.4x | 44.9x | −0.4x | |
PEG Ratio | 11.22 | 1.01 | 0.00 | |
Price/Book | 13.0x | 7.8x | 2.6x | |
Price / LTM Sales | 11.3x | 4.1x | 3.0x | |
Upside (Analyst Target) | 0.8% | 20.7% | 57.5% | |
Fair Value Upside | Unlock | 10.3% | 7.8% | Unlock |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Dr. Lal PathLabs (DLPA) Stock Price Today?
The Dr. Lal PathLabs stock price today is 1,950.40 INR.
What Stock Exchange Does Dr. Lal PathLabs Trade On?
Dr. Lal PathLabs is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Dr. Lal PathLabs?
The stock symbol for Dr. Lal PathLabs is "DLPA."
Does Dr. Lal PathLabs Pay Dividends? What’s The Current Dividend Yield?
The Dr. Lal PathLabs dividend yield is 0.82%.
What Is the Dr. Lal PathLabs Market Cap?
As of today, Dr. Lal PathLabs market cap is 325.83B INR.
What Is Dr. Lal PathLabs's Earnings Per Share (TTM)?
The Dr. Lal PathLabs EPS (TTM) is 32.40.
When Is the Next Dr. Lal PathLabs Earnings Date?
Dr. Lal PathLabs will release its next earnings report on Nov 04, 2026.
From a Technical Analysis Perspective, Is DLPA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Dr. Lal PathLabs Stock Split?
Dr. Lal PathLabs has split 1 times.
How Many Employees Does Dr. Lal PathLabs Have?
Dr. Lal PathLabs has 5206 employees.
What is the current trading status of Dr. Lal PathLabs (DLPA)?
As of Sep 29, 2026, Dr. Lal PathLabs (DLPA) is trading at a price of 1,950.40 INR, with a previous close of 1,950.40 INR. The stock has fluctuated within a day range of 1,930.60 INR to 1,971.40 INR, while its 52-week range spans from 1,272.60 INR to 2,038.60 INR.
What Is Dr. Lal PathLabs (DLPA) Price Target According to Analysts?
The average 12-month price target for Dr. Lal PathLabs is 1,976.54 INR, with a high estimate of 2300 INR and a low estimate of 1180 INR. 21 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +1.34% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.